United States · Financial press · Barron's
Why Pepsi’s Taco Bell Deal Is About Much More Than Fountain Drinks
The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment. The stock is poised to rally 30% or…
Read the full article on Barron's Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.barrons.com)
